# DC Mayor Proposes Partnership for Medical Marijuana THC Drinks > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/dc-cannabis-beverage-regulation-medical-marijuana-thc-drinks/ > **Published:** 2026-04-02T20:34:41-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:31:35-04:00 > **Clinical Summary:** Explore DC cannabis beverage regulation allowing medical marijuana and alcohol companies to partner on THC drinks, expanding patient access and safety. --- ✦ New CED Clinical Relevance #45 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. PolicyTHCIndustry Why This Matters This proposal could expand patient access to cannabis-derived beverages as a delivery method, which may offer advantages over smoking for patients with respiratory concerns or those seeking precise dosing. Clinicians should understand the regulatory landscape in their jurisdiction, as partnerships between medical and alcohol industries could create new safety considerations around labeling, potency standards, and potential drug interactions that affect clinical counseling. The $500 endorsement fee may lower barriers to entry for [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) companies, potentially increasing product availability and competition that could affect pricing and formulary decisions for patients. Clinical Summary The District of Columbia’s proposed regulatory framework would permit medical marijuana licensees to partner with alcohol beverage companies to produce THC-infused drinks, with cannabis producers paying an annual $500 endorsement fee to manufacture these products. This policy represents a significant shift in how jurisdictions structure cannabis beverage production and distribution, potentially creating new product categories that could appeal to patients seeking alternatives to traditional [cannabis consumption methods](https://cedclinic.com/cannabis-anxiety-relief-tips/). For clinicians, this development raises important questions about standardization, dosing accuracy, and patient education, as beverage-based THC products present unique pharmacokinetic profiles and abuse potential compared to other cannabis formulations. The involvement of established alcohol companies could improve manufacturing standards and quality control but also raises concerns about marketing practices and crossover appeal to non-medical consumers. Clinicians should anticipate increasing patient inquiries about cannabis beverages and prepare to counsel on appropriate dosing, onset times, and risks of overconsumption, particularly given the delayed effects typical of edible products. Healthcare providers should stay informed about local regulatory changes affecting available cannabis products in their region to provide evidence-based guidance on safe and appropriate use. Dr. Caplan’s Take “What concerns me clinically is that we’re moving toward THC beverages without the same dosing controls and patient education infrastructure we’ve built around traditional cannabis medicine, and aligning these products with alcohol distribution networks sends a troubling message about how we’re positioning cannabis in the marketplace when my patients need precise dosing and clear medical guidance.” Clinical Perspective Proposed partnerships between medical cannabis and alcohol beverage companies in Washington DC highlight an emerging commercial landscape that clinicians should monitor closely. While such collaborations could standardize cannabis beverage production and improve dosing consistency compared to unregulated products, they also introduce important concerns about marketing practices, dual-product messaging, and the potential normalization of cannabis use alongside alcohol—a combination with poorly understood pharmacokinetic interactions and unknown synergistic effects on cognition and motor function. Healthcare providers should be aware that patients may encounter these products as ostensibly “medical” options despite limited clinical evidence supporting cannabis beverages for specific therapeutic indications, and the regulatory pathway through commercial partnerships rather than rigorous clinical trials may obscure efficacy and safety data. When patients inquire about cannabis beverages, clinicians should clarify whether they are seeking symptom management for a defined condition versus recreational use, counsel on the lack of established dosing and interaction data (particularly with alcohol 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+DC+Mayor+Proposes+To+Let+Medical+Marijuana+And+Alcohol+Companies+Partner+On+THC+Drinks+%40drcaplan&url=https%3A%2F%2Fwww.marijuanamoment.net%2Fdc-mayor-proposes-to-let-medical-marijuana-and-alcohol-companies-partner-on-thc-drinks%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.marijuanamoment.net%2Fdc-mayor-proposes-to-let-medical-marijuana-and-alcohol-companies-partner-on-thc-drinks%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+DC+Mayor+Proposes+To+Let+Medical+Marijuana+And+Alcohol+Companies+Partner+On+THC+Drinks+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.marijuanamoment.net%2Fdc-mayor-proposes-to-let-medical-marijuana-and-alcohol-companies-partner-on-thc-drinks%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [CED Digest: 436 Items — March 14, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [CED Digest: 405 Items — March 12, 2026](https://cedclinic.com/alabama-medical-cannabis-sales-2026-spring-launch/) - [CED Digest: 392 Items — March 11, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) 📰 Source: [https://www.marijuanamoment.net/dc-mayor-proposes-to-let-medical-marijuana-and-alcohol-companies-partner-on-thc-drinks/](https://www.marijuanamoment.net/dc-mayor-proposes-to-let-medical-marijuana-and-alcohol-companies-partner-on-thc-drinks/) Further Reading CED Clinic BlogFirst stop, the Moon. Next stop, Mars? Why Nasa’s mission matters Evidence Watch[Cannabinoid exposure during pregnancy: Cardiorespiratory effects and offspring outcomes.](https://cedclinic.com/prenatal-cannabinoid-exposure-effects-cardiorespiratory-health/) Cannabis Policy Wire[CED Regulatory Digest, Since Last Digest, 2 items](https://cedclinic.com/ced-regulatory-digest-since-last-digest-2-items/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Washington Mayor Suggests Alcohol, Cannabis Companies Partner on THC Beverages](https://cedclinic.com/thc-beverages-partnership-alcohol-cannabis-collaboration/) Learn about similar proposals in Washington that encourage partnerships between alcohol and cannabis companies to produce THC beverages. [Read More](https://cedclinic.com/thc-beverages-partnership-alcohol-cannabis-collaboration/) [DC mayor proposes allowing cannabis drinks – NBC4 Washington](https://cedclinic.com/cannabis-beverages-pharmacokinetics-dosing-safety/) Coverage of the DC mayor's proposal to allow cannabis-infused drinks, highlighting regulatory and clinical considerations. [Explore Article](https://cedclinic.com/cannabis-beverages-pharmacokinetics-dosing-safety/) [What Happens When the Dispensary Starts Looking More Like a Pharmacy?](https://cedclinic.com/what-happens-when-the-dispensary-starts-looking-more-like-a-pharmacy/) Insights into evolving cannabis dispensary models and their impact on patient access and product safety. [Discover More](https://cedclinic.com/what-happens-when-the-dispensary-starts-looking-more-like-a-pharmacy/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).